Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer

Andrew D. Seidman; Larry Norton; Bonnie S. Reichman; John P.A. Crown; T. J. Yao; Thomas B. Hakes; David E. Lebwohl; Theresa A. Gilewski; Clifford A. Hudis; Antonella Surbone; Violante Currie; Raymond Klecker; Carlos Jamis-Dow; Jerry Collins; Linda Marks; Susan Quinlivan; Regina Berkery; Renzo Canetta; Nicole Onetlo; Susan Arbuck

doi:10.1159/000227414

Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer

Andrew D. Seidman, Larry Norton, Bonnie S. Reichman, John P.A. Crown, T. J. Yao, Thomas B. Hakes, David E. Lebwohl, Theresa A. Gilewski, Clifford A. Hudis, Antonella Surbone, Violante Currie, Raymond Klecker, Carlos Jamis-Dow, Jerry Collins, Linda Marks, Susan Quinlivan, Regina Berkery, Renzo Canetta, Nicole Onetlo, Susan Arbuck

Department of Radiology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

We treated 28 patients who had no prior chemotherapy for stage IV breast cancer and 51 patients with extensive prior exposure to other chemotherapeutic agents with a 24-hour infusion of Taxol (paclitaxel) as a single agent. Prophylactic recombinant human granulocyte colony-stimulating factor was administered routinely to ameliorate the anticipated dose-limiting toxicity of neutropenia. Nonhematologic toxicity was mild to moderate in most cases. Taxol was more active in patients with chemotherapy-naive stage IV disease, but activity was also observed in extensively treated patients as well. There is a strong clinical suggestion of at least partial noncross-resistance with doxorubicin. Taxol is a very promising agent for the treatment of metastatic breast cancer; its optimal application in this disease will be the subject of future trials.

Original language	English (US)
Pages (from-to)	33-39
Number of pages	7
Journal	Oncology (Switzerland)
Volume	51
DOIs	https://doi.org/10.1159/000227414
State	Published - 1994

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000227414

Cite this

Seidman, A. D., Norton, L., Reichman, B. S., Crown, J. P. A., Yao, T. J., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Hudis, C. A., Surbone, A., Currie, V., Klecker, R., Jamis-Dow, C., Collins, J., Marks, L., Quinlivan, S., Berkery, R., Canetta, R., Onetlo, N., & Arbuck, S. (1994). Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. Oncology (Switzerland), 51, 33-39. https://doi.org/10.1159/000227414

@article{fe50ca2d36bc4251805470f020e43f7d,

title = "Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer",

abstract = "We treated 28 patients who had no prior chemotherapy for stage IV breast cancer and 51 patients with extensive prior exposure to other chemotherapeutic agents with a 24-hour infusion of Taxol (paclitaxel) as a single agent. Prophylactic recombinant human granulocyte colony-stimulating factor was administered routinely to ameliorate the anticipated dose-limiting toxicity of neutropenia. Nonhematologic toxicity was mild to moderate in most cases. Taxol was more active in patients with chemotherapy-naive stage IV disease, but activity was also observed in extensively treated patients as well. There is a strong clinical suggestion of at least partial noncross-resistance with doxorubicin. Taxol is a very promising agent for the treatment of metastatic breast cancer; its optimal application in this disease will be the subject of future trials.",

author = "Seidman, {Andrew D.} and Larry Norton and Reichman, {Bonnie S.} and Crown, {John P.A.} and Yao, {T. J.} and Hakes, {Thomas B.} and Lebwohl, {David E.} and Gilewski, {Theresa A.} and Hudis, {Clifford A.} and Antonella Surbone and Violante Currie and Raymond Klecker and Carlos Jamis-Dow and Jerry Collins and Linda Marks and Susan Quinlivan and Regina Berkery and Renzo Canetta and Nicole Onetlo and Susan Arbuck",

year = "1994",

doi = "10.1159/000227414",

language = "English (US)",

volume = "51",

pages = "33--39",

journal = "Oncology",

issn = "0030-2414",

publisher = "S. Karger AG",

}

Seidman, AD, Norton, L, Reichman, BS, Crown, JPA, Yao, TJ, Hakes, TB, Lebwohl, DE, Gilewski, TA, Hudis, CA, Surbone, A, Currie, V, Klecker, R, Jamis-Dow, C, Collins, J, Marks, L, Quinlivan, S, Berkery, R, Canetta, R, Onetlo, N & Arbuck, S 1994, 'Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer', Oncology (Switzerland), vol. 51, pp. 33-39. https://doi.org/10.1159/000227414

TY - JOUR

T1 - Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer

AU - Seidman, Andrew D.

AU - Norton, Larry

AU - Reichman, Bonnie S.

AU - Crown, John P.A.

AU - Yao, T. J.

AU - Hakes, Thomas B.

AU - Lebwohl, David E.

AU - Gilewski, Theresa A.

AU - Hudis, Clifford A.

AU - Surbone, Antonella

AU - Currie, Violante

AU - Klecker, Raymond

AU - Jamis-Dow, Carlos

AU - Collins, Jerry

AU - Marks, Linda

AU - Quinlivan, Susan

AU - Berkery, Regina

AU - Canetta, Renzo

AU - Onetlo, Nicole

AU - Arbuck, Susan

PY - 1994

Y1 - 1994

N2 - We treated 28 patients who had no prior chemotherapy for stage IV breast cancer and 51 patients with extensive prior exposure to other chemotherapeutic agents with a 24-hour infusion of Taxol (paclitaxel) as a single agent. Prophylactic recombinant human granulocyte colony-stimulating factor was administered routinely to ameliorate the anticipated dose-limiting toxicity of neutropenia. Nonhematologic toxicity was mild to moderate in most cases. Taxol was more active in patients with chemotherapy-naive stage IV disease, but activity was also observed in extensively treated patients as well. There is a strong clinical suggestion of at least partial noncross-resistance with doxorubicin. Taxol is a very promising agent for the treatment of metastatic breast cancer; its optimal application in this disease will be the subject of future trials.

AB - We treated 28 patients who had no prior chemotherapy for stage IV breast cancer and 51 patients with extensive prior exposure to other chemotherapeutic agents with a 24-hour infusion of Taxol (paclitaxel) as a single agent. Prophylactic recombinant human granulocyte colony-stimulating factor was administered routinely to ameliorate the anticipated dose-limiting toxicity of neutropenia. Nonhematologic toxicity was mild to moderate in most cases. Taxol was more active in patients with chemotherapy-naive stage IV disease, but activity was also observed in extensively treated patients as well. There is a strong clinical suggestion of at least partial noncross-resistance with doxorubicin. Taxol is a very promising agent for the treatment of metastatic breast cancer; its optimal application in this disease will be the subject of future trials.

UR - http://www.scopus.com/inward/record.url?scp=0028028194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028028194&partnerID=8YFLogxK

U2 - 10.1159/000227414

DO - 10.1159/000227414

M3 - Article

C2 - 7526308

AN - SCOPUS:0028028194

SN - 0030-2414

VL - 51

SP - 33

EP - 39

JO - Oncology

JF - Oncology

ER -

Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this